Compliance with Cancer Quality Measures Over Time and Their Association with Survival Outcomes: The Commission on Cancer’s Experience with the Quality Measure Requiring at Least 12 Regional Lymph Nodes to be Removed and Analyzed with Colon Cancer Resections

Shulman, Lawrence N.; Browner, Amanda; Palis, Bryan E.; Mallin, Katherine; Kakade, Sumedh; Carp, Ned Z.; McCabe, Ryan; Winchester, David P.; Wong, Sandra L.; McKellar, Daniel P.

doi:10.1245/s10434-019-07323-w

Cited by 40 publications

(39 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNM stages were classified according to the American Joint Committee on Cancer guideline (7th Edition) but the detailed TNM categories (namely T, N, M) were lacking. It should be noted that there were two criteria for the category of patients according to their information related to lymph nodes (examined or metastatic) (38–40). Patients from the Second Affiliated Hospital (Wenzhou Medical University) were classified based on the number of examined lymph nodes during surgery.…”

Section: Methodsmentioning

confidence: 99%

Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer

et al. 2019

View full text Add to dashboard Cite

Tumor-infiltrating immune cells (TIICs) play essential roles in cancer development and progression. However, the association of TIICs with prognosis in colorectal cancer (CRC) patients remains elusive. Infiltration of TIICs was assessed using ssGSEA and CIBERSORT tools. The association of TIICs with prognosis was analyzed in 1,802 CRC data downloaded from the GEO (https://www.ncbi.nlm.nih.gov/geo/) and TCGA (https://portal.gdc.cancer.gov/) databases. Three populations of TIICs, including CD66b+ tumor-associated neutrophils (TANs), FoxP3+ Tregs, and CD163+ tumor-associated macrophages (TAMs) were selected for immunohistochemistry (IHC) validation analysis in 1,008 CRC biopsies, and their influence on clinical features and prognosis of CRC patients was analyzed. Prognostic models were constructed based on the training cohort (359 patients). The models were further tested and verified in testing (249 patients) and validation cohorts (400 patients). Based on ssGSEA and CIBERSORT analysis, the correlation between TIICs and CRC prognosis was inconsistent in different datasets. Moreover, the results with disease-free survival (DFS) and overall survival (OS) data in the same dataset also differed. The high abundance of TIICs found by ssGSEA or CIBERSORT tools can be used for prognostic evaluation effectively. IHC results showed that TANs, Tregs, TAMs were significantly correlated with prognosis in CRC patients and were independent prognostic factors (PDFS ≤ 0.001; POS ≤ 0.023). The prognostic predictive models were constructed based on the numbers of TANs, Tregs, TAMs (C-indexDFS&OS = 0.86; AICDFS = 448.43; AICOS = 184.30) and they were more reliable than traditional indicators for evaluating prognosis in CRC patients. Besides, TIICs may affect the response to chemotherapy. In conclusion, TIICs were correlated with clinical features and prognosis in patients with CRC and thus can be used as markers.

show abstract

Section: Methodsmentioning

confidence: 99%

Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In 2015, there were 17.5 M cancer cases worldwide, an increase by 33% with respect to 2005, and 8.7 M deaths . However, the recent developments in personalised medicine, the continuous progress of cancer research, and the advance of mini‐invasive surgical techniques have raised hope for patients and considerably improved cancer survival . At the same time, the increasing cost of cancer treatments leads to an ongoing debate regarding both the equity and the affordability of care from individual and societal perspectives .…”

Section: Introductionmentioning

confidence: 99%

Implementing successful systematic Patient Reported Outcome and Experience Measures (PROMs and PREMs) in robotic oncological surgery—The role of physicians

Lungu

Pennucci

Rosis

et al. 2019

Health Planning & Management

View full text Add to dashboard Cite

Int J Health Plann Mgmt. 2020;35:773-787. wileyonlinelibrary.com/journal/hpm 773 change in their relationship and communication with patients, as clinicians accept to have their job reviewed and are not afraid to be evaluated by their patients. K E Y W O R D S patient reported experience measures, patient reported outcome measures, PREMs, PROMs, robotic surgery 1 | BACKGROUND After the approval of the da Vinci Surgical System in 2000 by the Food and Drug Administration (FDA), the past two decades have been characterised by the increased diffusion of such systems and the manufacturer's data show that as of 30 September 2017, there was an installed base of 4271 units worldwide, of which more than 60% in the USA, followed by Europe and Asia 1-3 . Although initially it was employed mainly for urologic procedures (namely radical prostatectomy), the evolution of both the surgical technique and the technology made possible the introduction of robotic surgical systems to a broader range of surgical specialties: cardiac, colorectal, general surgery, gynaecology, head and neck, and thoracic surgery.At the same time, there was a rise in the oncological conditions (OCs) that pose a great challenge to health care systems due to their increasing prevalence and expenditure. Indeed, cancer is the second leading cause of death worldwide behind cardiovascular diseases. In 2015, there were 17.5 M cancer cases worldwide, an increase by 33%with respect to 2005, and 8.7 M deaths 4,5 . However, the recent developments in personalised medicine, the continuous progress of cancer research, and the advance of mini-invasive surgical techniques have raised hope for patients and considerably improved cancer survival 6-9 . At the same time, the increasing cost of cancer treatments leads to an ongoing debate regarding both the equity and the affordability of care from individual and societal perspectives 10,11 .The continuously growing number of oncological procedures delivered by means of robotic surgical systems and the controversial debate regarding their cost-effectiveness with respect to traditional surgery led to the need of performance measurement systems to evaluate the effects of treatments, including surgery, that are able to go beyond the traditional clinical view of mortality and complications rates [12][13][14][15] . Beside the objective outcome measurements evaluated by clinicians, there are also subjective measures such as patient satisfaction, quality of life, and patient experience.PROMs have received increased attention as a useful tool to evaluate the effects of treatments and the outcomes of patients who underwent robotic oncological surgery, as the importance of the patient's perspective on disease impact has been increasingly recognised 16 . PROMs data have been initially introduced in clinical trials in order to integrate the clinical data with the people's subjective perception of their health status and health-related quality of life 17 . Most studies present the results of clinical trials and focus on radical prostatec...

show abstract

“…The overall compliance improved from 52.8 to 92.1% during the study period and across all types of hospitals with compliant cases having better risk-adjusted survival than noncompliant cases. 12 Although differences remain between the various CoC programs, the absolute compliance gap between the NCI designated, academic centers, and the community hospitals has significantly reduced from 25 to 6.4%. The authors also noted that left sided tumors and community hospitals had lower compliance rates for ''12 RLN.''…”

mentioning

confidence: 99%

The Value of Commission on Cancer Accreditation: Improving Survival Outcomes by Enhancing Compliance with Quality Measures

Misra¹,

Ji²,

Yanala

et al. 2019

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

Compliance with Cancer Quality Measures Over Time and Their Association with Survival Outcomes: The Commission on Cancer’s Experience with the Quality Measure Requiring at Least 12 Regional Lymph Nodes to be Removed and Analyzed with Colon Cancer Resections

Cited by 40 publications

References 12 publications

Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer

Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer

Implementing successful systematic Patient Reported Outcome and Experience Measures (PROMs and PREMs) in robotic oncological surgery—The role of physicians

The Value of Commission on Cancer Accreditation: Improving Survival Outcomes by Enhancing Compliance with Quality Measures

Contact Info

Product

Resources

About